Clinical trial

An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT00949910

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Erlotinib Normalized identity: erlotinibView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE4

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2004-11-01

PhasePHASE4

Conditions

Non-Small Cell Lung Cancerverified · MONDO: non-small cell lung carcinoma

Interventions

ErlotinibDRUG · verified · RxNorm: erlotinib

Sponsors & collaborators

Hoffmann-La Rochelead sponsor

Mapped research locations

São PauloBrazil12 Mexico CityMexico10 SeoulSouth Korea9 RomaItaly6 TaipeiTaiwan5 BrusselsBelgium5 ViennaAustria5 Buenos AiresArgentina5 AmsterdamNetherlands5 BeijingChina4 AnkaraTurkey (Türkiye)4 Rio de JaneiroBrazil4

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00949910 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.